Source: Annual Congress 2002 - Drug resistance
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
M. V. Fedorova, E. Y. Stoukalina, K. A. Lipsky, S. A. Zhilina, A. P. Duntau, E. V. Medvedeva, E. M. Karpov, V. G. Kononenko, L. V. Alekseev (Novosibirsk, Russia). The experience of overcome of Mcb.tuberculosis resistance to antituberculosis drugs. Eur Respir J 2002; 20: Suppl. 38, 3831

Member's Comments

No comment yet.

Related content which might interest you: Initial antituberculosis drugs resistance Source: Eur Respir J 2006; 28: Suppl. 50, 12s Year: 2006 Resistance to second-line anti-tuberculosis drugs: new drug resistant TB treatment problem Source: Annual Congress 2007 - Drug-resistant and multidrug-resistant tuberculosis Year: 2007 Therapeutic drug monitoring to prevent acquired drug resistance of fluoroquinolones in the treatment of tuberculosis Source: Eur Respir J , 49 (4)  1700173; DOI: 10.1183/13993003.00173-2017 Year: 2017 Therapeutic drug monitoring to prevent acquired drug resistance of fluoroquinolones in the treatment of tuberculosis Source: Eur Respir J , 49 (4)  1700317; DOI: 10.1183/13993003.00317-2017 Year: 2017 Rational use of tuberculosis drugs to prevent the development of drug resistance Source: Annual Congress 2012 - MDR- and XDR-TB: epidemiological and public health overview Year: 2012 Impact of resistance to first-line and injectable drugs on treatment outcomes in MDR-TB Source: Eur Respir J 2009; 33: 581-585 Year: 2009 Rational use of anti-tuberculosis drugs in the EU: better patient care and less drug resistance Source: Eur Respir J 2012; 39: 802-804 Year: 2012 Prevalance of initial and acquired resistance to antituberculosis drugs in our clinic Source: Eur Respir J 2005; 26: Suppl. 49, 653s Year: 2005 New drugs and drug regimens in the treatment of chronic and MDR-TB - what is on the horizon? Source: Annual Congress 2005 - Challenges in the management of pulmonary tuberculosis: a continuous clinical problem Year: 2005 Evaluation the drug susceptibility testing and the prevalence of resistance to antituberculosis drugs in a chronic department Source: Eur Respir J 2003; 22: Suppl. 45, 520s Year: 2003 A Cuban successful history on antituberculosis treatment and drug resistance surveillance Source: Annual Congress 2007 - Specific problems in caring for multidrug-resistant tuberculosis and tuberculosis/HIV cases Year: 2007 Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes Source: Eur Respir J 2013; 42: 156-168 Year: 2013 Shortened multidrug-resistant tuberculosis regimens overcome low-level fluoroquinolone resistance Source: Eur Respir J, 49 (6) 1700223; 10.1183/13993003.00223-2017 Year: 2017 Adverse effects of second-line drugs during the treatment of multidrug resistant tuberculosis patients Source: Eur Respir J 2005; 26: Suppl. 49, 650s Year: 2005 The main clinical problem of increasing resistance of Mycobacterium tuberculosis (MT) to first-line anti-TB drugs Source: Eur Respir J 2005; 26: Suppl. 49, 654s Year: 2005 The problem of one drug resistance in tuberculosis Source: Eur Respir J 2006; 28: Suppl. 50, 858s Year: 2006 Second-line anti-tuberculosis drug concentrations for susceptibility testing in the MODS assay Source: Eur Respir J 2013; 41: 1163-1171 Year: 2013 Sparfloxacin in the treatment of drug resistant tuberculosis or intolerance of first line therapy Source: Eur Respir J 2001; 17: 641-646 Year: 2001 The side-effects of TB therapy: myth and reality Source: Annual Congress 2005 - PG10 - The management of tuberculosis: tradition and novelties Year: 2005